Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing

Pengyuan Liu(Medical College of Wisconsin), Carl Morrison(Roswell Park Comprehensive Cancer Center), Liang Wang(Mayo Clinic in Florida), Donghai Xiong(Medical College of Wisconsin), Peter T. Vedell(Medical College of Wisconsin), Peng Cui(Medical College of Wisconsin), Xing Hua(Medical College of Wisconsin), Feng Ding(Medical College of Wisconsin), Yan Lü(Medical College of Wisconsin), Michael A. James(Medical College of Wisconsin), John D. Ebben(Medical College of Wisconsin), Haiming Xu(Medical College of Wisconsin), Alex A. Adjei(Roswell Park Comprehensive Cancer Center), Karen Head(Roswell Park Comprehensive Cancer Center), Jaime Wendt Andrae(Medical College of Wisconsin), Michael Tschannen(Medical College of Wisconsin), Howard J. Jacob(Medical College of Wisconsin), Jing Pan(Medical College of Wisconsin), Qi Zhang(Medical College of Wisconsin), Françoise Van den Bergh(Medical College of Wisconsin), Haijie Xiao(Medical College of Wisconsin), Ken C. Lo(La Roche College), Jigar Patel(La Roche College), Todd Richmond(La Roche College), Mary-Anne Watt(La Roche College), Thomas Albert(La Roche College), Rebecca R. Selzer(La Roche College), Marshall W. Anderson(Medical College of Wisconsin), Jiang Wang(University of Cincinnati Medical Center), Yian Wang(Washington University in St. Louis), Sandra L. Starnes(University of Cincinnati Medical Center), Ping Yang(Mayo Clinic in Florida), Ming You(Medical College of Wisconsin)
Carcinogenesis
April 17, 2012
Cited by 207Open Access
Full Text

Abstract

Lung cancer is the leading cause of cancer-related death, with non-small cell lung cancer (NSCLC) being the predominant form of the disease. Most lung cancer is caused by the accumulation of genomic alterations due to tobacco exposure. To uncover its mutational landscape, we performed whole-exome sequencing in 31 NSCLCs and their matched normal tissue samples. We identified both common and unique mutation spectra and pathway activation in lung adenocarcinomas and squamous cell carcinomas, two major histologies in NSCLC. In addition to identifying previously known lung cancer genes (TP53, KRAS, EGFR, CDKN2A and RB1), the analysis revealed many genes not previously implicated in this malignancy. Notably, a novel gene CSMD3 was identified as the second most frequently mutated gene (next to TP53) in lung cancer. We further demonstrated that loss of CSMD3 results in increased proliferation of airway epithelial cells. The study provides unprecedented insights into mutational processes, cellular pathways and gene networks associated with lung cancer. Of potential immediate clinical relevance, several highly mutated genes identified in our study are promising druggable targets in cancer therapy including ALK, CTNNA3, DCC, MLL3, PCDHIIX, PIK3C2B, PIK3CG and ROCK2.


Related Papers

No related papers found

Powered by citation graph analysis